Eric Singhi, Assistant Professor in the Department of General Oncology at The University of Texas MD Anderson Cancer Center, shared a post on X:
“Phase 2 SKIPPirr: Reducing IRRs with IV amivantamab in EGFR+ mNSCLC post osimertinib/chemo
Oral dexamethasone 8mg BID (Day -2, -1 and 1 dose 1 h pre-infusion)
IRRs ~3-fold (22.5% v 67.4%)
IMO practice-changing.”
Authors: Luis Paz-Ares, Ji-Youn Han, Jin-Yuan Shih, Céline Mascaux, Upal Basu Roy, Jon Zugazagoitia, Yu Jung Kim, Chao-Hua Chiu, Sang-We Kim, Ernest Nadal, Ignacio Gil-Bazo, Sean P. Murphy, Bailey G. Anderson, Yichuan Xia, George Wang, Joshua M. Bauml, Marc Chioda, Jairo Simoes, Parthiv J. Mahadevia, Gilberto Lopes.
